Five-Year Summary

Track our recent performance by year, region and major product group.

All figures are in US$ million unless stated otherwise

2018-19 
Constant Currency(1)
 
2018-19 
Reported(2)
 
2017-18 
Reported
2016-17 
Reported
2015-16 
Reported 
2014-15 
Reported
 
Total Operating Revenue  8,757  8,539 7,915 6,947 6,115 5,612
Sales Revenue  8,418  8,205 7,588 6,616 5,909 5,459
R&D Investment  853  832 702 667 614 463
Profit before Income Tax Expense  2,465  2,341 2,281 1,690 1,556 1,714
Net profit after tax  2,015  1,919 1,729 1,337 1,242 1,379
Net cash inflow from Operating Activities    1,644 1,902 1,247 1,179 1,364
Capital investment    992 992 861 566 414
Return on Invested Capital (%)    24.3 25.9 24.5 26.8(3) 31.70
Basic earnings per share ($)    4.236 3.822 2.937 2.689 2.923
Dividend per share ($)    1.850 1.720 1.360 1.26 1.24

(1) Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further details please refer to CSL’s Financial Statements for the Full Year ended 2019 (Directors’ Report).
(2) The Group’s reported results are in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS).
(3) 2016 figure includes the gain on acquisition of Novartis’ global influenza vaccine business of US$176.1 million.

 

Get our latest news in your inbox

mail@example.com
First name
Last name
Country

Thanks!

Thank you for subscribing
to the CSL newsletter